Literature DB >> 9117376

The progress of cognitive decline in multiple sclerosis. A controlled 3-year follow-up.

P Kujala1, R Portin, J Ruutiainen.   

Abstract

The purpose of this study was to illustrate how cognitive functioning evolves over time in patients with multiple sclerosis. We followed the evolution of cognitive performances in two clinically and demographically similar multiple sclerosis groups, the 'cognitively preserved' (n = 20) and the 'cognitively mildly deteriorated' (n = 22), and in healthy controls (n = 34). We conducted the follow-up examination using the Mild Deterioration Battery, the Mini-Mental State Examination, and a set of additional neuropsychological measures after an interval of 3 years. The drop-out rate in our study was only 5%. The 'cognitively preserved' multiple sclerosis group showed substantial neuropsychological stability by performing as well as the controls both at baseline and at follow-up. By contrast, the initially 'cognitively mildly deteriorated' group demonstrated progressive cognitive decline on many neuropsychological tests. The intermediate-length screening battery, the Mild Deterioration Battery, was sensitive to this decline, whereas the briefer Mini-Mental State Examination was not. The progressive cognitive decline could not be predicted from other disease variables. The study demonstrated that intact cognitive functioning in multiple sclerosis may remain stable, whereas incipient cognitive decline seems to be widespread and progressive in nature. Thus, progressive cognitive deterioration should be considered as one of the characteristics of multiple sclerosis.

Entities:  

Mesh:

Year:  1997        PMID: 9117376     DOI: 10.1093/brain/120.2.289

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  38 in total

1.  Neuropsychological and psychiatric aspects of multiple sclerosis: preliminary investigation of discrete profiles across neurological subtypes.

Authors:  Marina Katsari; Dimitrios Kasselimis; Gerasimos Gasparinatos; Roubina Antonellou; Konstantinos Voumvourakis
Journal:  Neurol Sci       Date:  2016-01-07       Impact factor: 3.307

2.  Prevalence and incidence of cognitive impairment in multiple sclerosis: a population-based survey in Catania, Sicily.

Authors:  Francesco Patti; Alessandra Nicoletti; Silvia Messina; Elisa Bruno; Salvatore Lo Fermo; Graziella Quattrocchi; Clara Grazia Chisari; Davide Maimone; Sabina Cilia; Mario Zappia
Journal:  J Neurol       Date:  2015-02-07       Impact factor: 4.849

Review 3.  White matter in learning, cognition and psychiatric disorders.

Authors:  R Douglas Fields
Journal:  Trends Neurosci       Date:  2008-06-05       Impact factor: 13.837

4.  Changes in Fatigue and Cognition in Patients with Relapsing Forms of Multiple Sclerosis Treated with Natalizumab: The ENER-G Study.

Authors:  Jeffrey Wilken; Robert L Kane; Cynthia L Sullivan; Mark Gudesblatt; Sylvia Lucas; Robert Fallis; Xiaojun You; Pam Foulds
Journal:  Int J MS Care       Date:  2013

5.  ERK1/2 Activation in Preexisting Oligodendrocytes of Adult Mice Drives New Myelin Synthesis and Enhanced CNS Function.

Authors:  Marisa A Jeffries; Kelly Urbanek; Lester Torres; Stacy Gelhaus Wendell; Maria E Rubio; Sharyl L Fyffe-Maricich
Journal:  J Neurosci       Date:  2016-08-31       Impact factor: 6.167

6.  MRI predictors of cognitive outcome in early multiple sclerosis.

Authors:  M S A Deloire; A Ruet; D Hamel; M Bonnet; V Dousset; B Brochet
Journal:  Neurology       Date:  2011-03-29       Impact factor: 9.910

7.  Neuropsychological deficits but not coping strategies are related to physical disability in multiple sclerosis.

Authors:  Claus G Haase; Marc Lienemann; Pedro M Faustmann
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2007-11-07       Impact factor: 5.270

8.  Oligodendrocyte-specific loss of Cdk5 disrupts the architecture of nodes of Ranvier as well as learning and memory.

Authors:  Fucheng Luo; Jessie Zhang; Kathryn Burke; Rita R Romito-DiGiacomo; Robert H Miller; Yan Yang
Journal:  Exp Neurol       Date:  2018-05-02       Impact factor: 5.330

9.  Effects of single dose mixed amphetamine salts--extended release on processing speed in multiple sclerosis: a double blind placebo controlled study.

Authors:  Sarah A Morrow; Heather Rosehart
Journal:  Psychopharmacology (Berl)       Date:  2015-08-21       Impact factor: 4.530

10.  OLIGODENDROCYTE VULNERABILITY FOLLOWING TRAUMATIC BRAIN INJURY IN RATS: EFFECT OF MODERATE HYPOTHERMIA.

Authors:  George Lotocki; Juan de Rivero Vaccari; Ofelia Alonso; Juliana Sanchez Molano; Ryan Nixon; W Dalton Dietrich; Helen M Bramlett
Journal:  Ther Hypothermia Temp Manag       Date:  2011-04-05       Impact factor: 1.286

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.